BR112013000613A2 - composições secas e dispositivos que contêm tais composições secas - Google Patents

composições secas e dispositivos que contêm tais composições secas

Info

Publication number
BR112013000613A2
BR112013000613A2 BR112013000613A BR112013000613A BR112013000613A2 BR 112013000613 A2 BR112013000613 A2 BR 112013000613A2 BR 112013000613 A BR112013000613 A BR 112013000613A BR 112013000613 A BR112013000613 A BR 112013000613A BR 112013000613 A2 BR112013000613 A2 BR 112013000613A2
Authority
BR
Brazil
Prior art keywords
dry compositions
compositions
dry
devices containing
devices
Prior art date
Application number
BR112013000613A
Other languages
English (en)
Portuguese (pt)
Inventor
Bjorn Klem
Norbert Lange
Original Assignee
Photocure Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure Asa filed Critical Photocure Asa
Publication of BR112013000613A2 publication Critical patent/BR112013000613A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112013000613A 2010-07-09 2011-07-08 composições secas e dispositivos que contêm tais composições secas BR112013000613A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10251232 2010-07-09
PCT/EP2011/061688 WO2012004399A1 (en) 2010-07-09 2011-07-08 Dry compositions and devices containing such dry compositions for use in photodynamic therapy or photodynamic diagnosis

Publications (1)

Publication Number Publication Date
BR112013000613A2 true BR112013000613A2 (pt) 2016-06-28

Family

ID=44628087

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013000613A BR112013000613A2 (pt) 2010-07-09 2011-07-08 composições secas e dispositivos que contêm tais composições secas

Country Status (9)

Country Link
US (1) US20130178787A1 (cg-RX-API-DMAC10.html)
EP (1) EP2590714B1 (cg-RX-API-DMAC10.html)
JP (1) JP5991970B2 (cg-RX-API-DMAC10.html)
KR (1) KR101842732B1 (cg-RX-API-DMAC10.html)
AU (1) AU2011275695B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013000613A2 (cg-RX-API-DMAC10.html)
CA (1) CA2804337A1 (cg-RX-API-DMAC10.html)
ES (1) ES2620780T3 (cg-RX-API-DMAC10.html)
WO (1) WO2012004399A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
CN102670577B (zh) * 2012-05-18 2018-04-13 上海复旦张江生物医药股份有限公司 一种光敏剂组合物、其使用方法及用途
US20140067024A1 (en) 2012-08-30 2014-03-06 Photocure Asa Dual panel photodynamic therapy lamp
GB201221123D0 (en) 2012-11-23 2013-01-09 Photocure As Device for photodynamic treatment
GB201306369D0 (en) 2013-04-09 2013-05-22 Photocure As Irradiation device
CN105683752B (zh) * 2013-06-21 2019-03-29 国立大学法人冈山大学 基于异常活化细胞检测的恶性肿瘤的检查方法及去除异常活化细胞血液循环回输治疗装置
GB201522398D0 (en) 2015-12-18 2016-02-03 Photocure As Device for photodynamic therapy
DK3641882T3 (da) * 2017-06-21 2023-12-18 Photocure Asa Fremgangsmåde til fremstilling af en flydende farmaceutisk sammensætning og indretning til anvendelse i en sådan fremgangsmåde
US20250188521A1 (en) 2022-03-10 2025-06-12 Singular Genomics Systems, Inc. Nucleic acid delivery scaffolds
WO2026158624A1 (en) * 2025-01-26 2026-07-30 Jiangsu Yahong Meditech Co., Ltd. Semi-solid pharmaceutical compositions containing stearic acid and palmitic acid

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996023543A1 (en) * 1995-01-30 1996-08-08 Angiomedics Ii Incorporated Photolytic drug delivery systems
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
GB2360459B (en) * 2000-03-23 2002-08-07 Photo Therapeutics Ltd Therapeutic light source and method
US6551346B2 (en) * 2000-05-17 2003-04-22 Kent Crossley Method and apparatus to prevent infections
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0118251D0 (en) 2001-07-26 2001-09-19 Photocure Asa Method
EP1423116A1 (en) * 2001-08-14 2004-06-02 Biotie Therapies Corp. Method of treating alcoholism or alcohol abuse
EP1312353A1 (en) 2001-11-16 2003-05-21 Ecole Polytechnique Federale De Lausanne (Epfl) Method for hair removal
DE10202487A1 (de) * 2002-01-23 2003-07-31 Photonamic Gmbh & Co Kg Dermales Applikationssystem für Aminolävulinsäure-Derivate
US20050085455A1 (en) * 2003-10-16 2005-04-21 Light Sciences Corporation Photodynamic therapy for local adipocyte reduction
CA2457214A1 (en) * 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
GB0424833D0 (en) 2004-11-10 2004-12-15 Photocure Asa Method
JP2008526418A (ja) 2005-01-18 2008-07-24 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 放射線を放出するための電子制御されるカプセル
ES2668959T3 (es) * 2005-03-31 2018-05-23 Esther Mayer Dispositivo de sonda para la fotobiomodulación del tejido que reviste una cavidad corporal
US20070260231A1 (en) * 2005-04-21 2007-11-08 Ondine International, Ltd. Optical probe for delivery of light
DE102006001736A1 (de) * 2006-01-13 2007-07-26 Margull, Matthias, Dipl.-Ing. Vorrichtung zur Applikation von monochromatischem Licht in Körperöffnungen
GB0608315D0 (en) * 2006-04-27 2006-06-07 Univ St Andrews Light emitting device for use in therapeutic and/or cosmetic treatment
US8292935B2 (en) * 2006-09-12 2012-10-23 Bistitec Pharma Marketing Ltd Photonic device and method for treating cervical dysplasia
GB0724279D0 (en) * 2007-12-12 2008-01-23 Photocure Asa Use
GB0816027D0 (en) * 2008-09-03 2008-10-08 Lumicure Ltd Controlled light emitting apparatus
GB0823472D0 (en) * 2008-12-23 2009-01-28 Photocure Asa Product
GB0900461D0 (en) * 2009-01-12 2009-02-11 Photocure Asa Photodynamic therapy device
WO2010142457A1 (en) 2009-06-11 2010-12-16 Photocure Asa Semi-solid compositions and pharmaceutical products

Also Published As

Publication number Publication date
CN103118742A (zh) 2013-05-22
AU2011275695B2 (en) 2014-07-31
EP2590714B1 (en) 2017-03-08
JP5991970B2 (ja) 2016-09-14
KR20130083436A (ko) 2013-07-22
US20130178787A1 (en) 2013-07-11
CA2804337A1 (en) 2012-01-12
KR101842732B1 (ko) 2018-05-14
EP2590714A1 (en) 2013-05-15
JP2013532035A (ja) 2013-08-15
WO2012004399A1 (en) 2012-01-12
ES2620780T3 (es) 2017-06-29
AU2011275695A1 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
BR112012029959A2 (pt) compostos de carbamato de mentila como ativos para clareamento de pele e/ou cabelo
BR112015008480A2 (pt) compostos de benzeno substituído
UA107667C2 (uk) Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EP4140487A8 (en) Combination therapy for treating cancer
WO2012079092A3 (en) Testosterone undecanoate compositions
MX395136B (es) Composiciones farmaceuticas y metodos de administracion relacionados.
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
SG176687A1 (en) Solid compositions comprising 5-aminolevulinic acid
BR112014012056A8 (pt) compostos farmacêuticos
NZ607580A (en) N-heteroaryl compounds
CL2013001459A1 (es) Compuestos derivados de quinazolincarboxamida azetidina; proceso para prepararlos; composicion farmaceutica que los comprende; set (kit); y su uso para el tratamiento de enfermedades hiperproliferativas tales como cancer, inflamacion, pancreatitis o enfermedad renal, dolor, hiperplasia benigna de piel entre otras.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
EA201590697A1 (ru) Производные кетамина
GB2476446A (en) Topical treatment of skin infection
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
EA201591378A1 (ru) Композиции неорганических наночастиц в комбинации с ионизирующим излучением для лечения рака
EA201170117A1 (ru) Противоаллергические биополимеры морского происхождения
MX2012005689A (es) Analogos de acido araquidonico y metodos para el tratamiento analgesico utilizando los mismos.
CL2012001322A1 (es) Compuestos derivados de piridinopiridinona, inhibidores pdgf; procedimiento de preparacion de estos; composición farmacéutica que los comprende; combinación farmacéutica; y su uso en el tratamiento del cancer, ateroesclerosis, enfermedades cardiacas, diabetes, renales, entre otras.
PE20151607A1 (es) Formulaciones de compuestos organicos
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
PT2459153E (pt) Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2522 DE 07-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.